The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable interest within the healthcare community. This groundbreaking dual GIP and GLP-1 target medication suggests to deliver significant improvements in weight loss compared to previous therapies. Initial patient data have indicated marked declines in weight , possibly m